Bunnik, The Netherlands, 2 September 2011. AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) for the treatment of severe inflammatory diseases, today announced the appointment of Erik van den Berg, previously VP Business Development of AM-Pharma as CEO of the company.
Bart Wuurman, who has led the company the past 4 years decided to take on a new challenge in his career.
Eric Claassen, Chairman of AM-Pharma, commented:
“Bart has made a distinctive contribution to the development of AM-Pharma and I would like to thank him for his efforts in turning AM-Pharma into a focused organization, and for his role in preparing a new round of upcoming financing for the company.”
Bart Wuurman, said:
“I am proud to have worked with the AM Pharma team during the past four years. In this period the team was able to generate key clinical data that supports further development of AM-Pharma’s product for an indication of high medical need.”
For more information, please contact:
Erik van den Berg
Tel: +31 (0)30 259 8838
For media enquiries:
College Hill Life Sciences
Dr Douglas Pretsell/Daniel Gooch
Tel: +44 (0)20 7866 7866
Notes for Editors
About AM-Pharma www.am-pharma.com
AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase as protective treatment of severe inflammatory diseases. AM-Pharma is based in Bunnik, The Netherlands. Based on the strong results of the Phase II trials with bovine Alkaline Phosphatase in Acute Kidney Injury and a Phase II trial in severe Ulcerative Colitis, AM-Pharma will replace bovine Alkaline Phosphatase with its proprietary recombinant form of human Alkaline Phosphatase. This recombinant material will be used in future trials and for commercialization.